{
  "docId": "019de070-ef32-76c0-a934-5684fd214b03",
  "docSlug": "fcead70b79df47e131186f14d3be986d",
  "documentTitle": "Thermo Fisher | Mergers and Acquisitions Presentation Deck | 12 slides",
  "authorId": "thermo-fisher",
  "authorName": "Thermo Fisher Scientific",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 12,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "other",
  "function": "establish_context",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-ef32-76c0-a934-5684fd214b03/4",
  "deckHref": "/decks/019de070-ef32-76c0-a934-5684fd214b03",
  "deckJsonHref": "/decks/019de070-ef32-76c0-a934-5684fd214b03.json",
  "deckAnchorHref": "/decks/019de070-ef32-76c0-a934-5684fd214b03#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.14,
        "x": 0.84,
        "y": 0.02
      },
      "kind": "image",
      "text": "Thermo Fisher Scientific",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "970af7bc-ebf8-4ea9-a59f-9662375aba71",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.93,
        "x": 0.037,
        "y": 0.288
      },
      "kind": "list",
      "text": "Establishes Thermo Fisher as a global leader in the attractive high growth clinical research services industry\nNatural extension of our capabilities to meet the needs of pharma and biotech, our largest and fastest growing end market\nCreates meaningful benefit for our customers\nThe acquisition further enables us to partner with our customers as they move from a scientific idea to an approved medicine\nCompelling combination creates the opportunity to meaningfully reduce both the time and cost to bring innovative therapies to market\nGenerates substantial synergies and delivers attractive financial benefits to create shareholder value",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc398bc0-e395-434a-b11e-691488d559ee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.59,
        "x": 0.025,
        "y": 0.04
      },
      "kind": "title",
      "text": "Strategic rationale for acquisition of PPD",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76f37e15-745b-412f-a9a9-18edcb42bc5a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 4,
      "beatId": "3252463d-1c58-4966-94d4-f747ff1a4927",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Problem & Complication",
      "beatSlug": "consultants-gambit-problem-complication",
      "evidence": "The strategic rationale and role of clinical research organizations highlight the need for the acquisition.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 12,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "a1507e9d-bc0b-4b68-9e0f-630db74cf98e",
      "evidence": "The deck uses a golden circle approach, starting with what (creating customer and shareholder value), then how (strategic rationale, market sizing, and customer benefits), and implicitly why (compelling financial profile and increasing presence in the fastest growing end market).",
      "position": 0,
      "objective": "Why this acquisition?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    },
    {
      "to": 5,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "9444679a-ec83-4ceb-9dd0-11f4c9adb7d1",
      "evidence": "The strategic rationale and role of clinical research organizations imply the cost of inaction.",
      "position": 1,
      "objective": "What if we don't acquire PPD?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}